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Introduction
============

Clinical practice guidelines recommend targeting breast and colorectal cancer screening to healthy older patients who have a substantial life expectancy.[@ref1] [@ref2] A major rationale for this recommendation is that cancer screening is unlikely to benefit patients with a short life expectancy because the benefit from screening is not immediate. Screening leads to benefit by finding an asymptomatic cancer at an early stage which, if left untreated, would cause symptoms or death years later. Thus, screening interventions have a "time lag to benefit." This period starts from the date of screening, when the patient is exposed to the risks of screening (for example, pain, worry, and potential complications such as perforation or infection[@ref3] [@ref4]), to the point in time when the benefits (for example, reduction in cancer mortality) are observed in randomized screening trials. For patients with a life expectancy shorter than the time lag to benefit, cancer screening exposes this group to immediate risks with little chance that they would survive long enough to benefit.

However, it is unclear how long a patient needs to live to potentially derive survival benefit from breast and colorectal cancer screening. Randomized controlled trials of screening have focused on the magnitude of benefit rather than when those benefits occur, leading to varying recommendations about the time lag to benefit. For example, the United States Preventive Services Task Force (USPSTF) suggests the time lag to benefit for colorectal cancer screening is at least seven years,[@ref1] whereas the American Geriatrics Society estimates three to five years.[@ref5] A pooled quantitative estimate of this period would allow clinicians to juxtapose a screening test's time lag to benefit to a patient's life expectancy, to determine whether an individual patient is likely to benefit from screening. Although a recent systematic review[@ref6] and accompanying website ([www.eprognosis.com](http://www.eprognosis.com/)) facilitate the use of published mortality indexes to estimate a patient's life expectancy,[@ref7] [@ref8] much less is known about the time lag to benefit for cancer screening.

Thus, we conducted survival meta-analyses of the major trials of mammography (for breast cancer screening) and fecal occult blood testing (for colorectal cancer screening) to determine the tests' time lag to benefit. Because limited life expectancy is predominantly a consideration for older adults, we excluded studies that focused solely on younger patients. We focused on calculating the number of years needed to reach various thresholds of benefit using the absolute risk reduction in cancer specific mortality. These absolute risk reductions ranged from preventing one cancer death per 10 000 people screened to preventing one cancer death per 500 people screened. We used this range to show the spectrum of time lags to benefit for breast and colorectal cancer screening.

Methods
=======

Design overview
---------------

Since breast and colorectal cancer screening has been the subject of extensive research, we focused on the largest, most rigorously conducted, randomized clinical trials identified by the Cochrane Collaboration and USPSTF reviews between 1999 and 2009 (fig 1[](#fig1){ref-type="fig"}).[@ref1] [@ref2] [@ref9] [@ref10] [@ref11] All trials examined multiple rounds of screening, leading us to focus on the time lag to benefit for multiple rounds of screening, rather than for a single screening test.

![**Fig 1** Trial selection criteria. FOBT=fecal occult blood test; HIP=Health Insurance Plan; CNBSS=Canadian National Breast Screening Study. Kopparberg and Ostergotland studies make up the Two-County Study.[@ref16] We used the synthesized data from the Combined Swedish Trials for our analysis[@ref22]](lees002063.f1_default){#fig1}

For colorectal cancer screening, we focused on fecal occult blood tests rather than flexible sigmoidoscopy or colonoscopy since the methodological rigor of these trials has not been evaluated in Cochrane or USPSTF reviews. We excluded trials that had no patients aged over 50 years (mammography trials: Canadian National Breast Screening Study I,[@ref12] Malmo II,[@ref13] and UK Age study[@ref14]) or were rated as "likely biased" in the Cochrane review (mammography trials: Edinburgh[@ref15] and Kopparberg[@ref16]).

We obtained all publications for each eligible trial in our meta-analysis: four trials for colorectal cancer screening and five trials for breast cancer screening. For breast cancer, our final analytic sample of studies differed substantially from the Cochrane review. This was because we excluded studies that did not include older women, and we included studies that the Cochrane review rated as "suboptimal" but not "likely biased" (Health Insurance Plan-New York, Goteborg, and Stockholm).[@ref23] [@ref24] [@ref26]

Settings, population, intervention, outcome, and follow-up
----------------------------------------------------------

For colorectal cancer screening (using fecal occult blood tests), we examined population based, randomized controlled trials conducted in Denmark (Funen),[@ref17] the United Kingdom (Nottingham),[@ref18] Sweden (Goteborg),[@ref19] and the US (Minnesota) (table 1[](#tbl1){ref-type="table"}).[@ref20] [@ref21] All four trials were large; the number of participants ranged from 30 964 to 150 251, enrolling patients aged 45-80 years. Although we focused on patients older than 50 years, we included some younger patients if they were part of a study with older patients because we did not have access to patient level data. Participants in each study were randomized to receive an invitation to screen versus usual care. Screening regimens varied by individual study (range 2-11 rounds of fecal occult blood tests). The primary outcome in these trials was colorectal cancer mortality, and follow-up ranged from eight to 19 years.
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Trial characteristics

                                                              Sample size (No)   Age range (years)   Follow-up range (years)   Absolute risk reduction (95% CI)   Intervention           
  ----------------------------------------------------------- ------------------ ------------------- ------------------------- ---------------------------------- ---------------------- -------------------------------------------
  **Colorectal cancer screening (fecal occult blood test)**                                                                                                                              
  Minnesota (annual)^20,21^\*                                 30 964             50-80               ≤18                       0.08 (−0.04 to 0.21)               0.23 (0.06 to 0.40)    11 rounds, annual
  Minnesota (biennial)^20,21^\*                               30 981             50-80               ≤18                       −0.09 (−0.23 to 0.05)              0.04 (−0.14 to 0.23)   6 rounds, biennial
  Nottingham^18^                                              150 251            45-74               11 (8-18)                 0.09 (0.02 to 0.16)                0.13 (0.04 to 0.22)    2-5 rounds, biennial
  Funen^17^†                                                  61 933             45-75               ≤10                       0.10 (−0.02 to 0.22)               ---                    5 rounds, biennial
  Goteborg^19^                                                68 308             59-65               (11-19)                   0.003 (−0.08 to 0.09)              0.07 (−0.04 to 0.19)   2-3 rounds (rescreened 1, 2, or 10 years)
  **Breast cancer screening (mammography)**                                                                                                                                              
  Health Insurance Plan-New York^26^†                         61 004             40-64               ≤10                       0.10 (0.00 to 0.20)                ---                    4 rounds, annual
  Combined Swedish trials^22^‡                                110 385            55-74               16 (14-22)                0.10 (0.04 to 0.16)                0.14 (0.06 to 0.21)    ---
  Malmo I^22,24^§                                             25 299             45-70               19 (18-20)                0.023                              0.095                  6-8 rounds, every 18-24 months
  Ostergotland^16,22^§                                        44 743             40-74               17 (16-19)                0.029                              0.052                  2-4 rounds, every 24-33 months
  Stockholm^22,25^§                                           26 532             40-65               15 (14-16)                0.032                              0.030                  2 rounds, every 28 months
  Goteberg^22,23^§                                            13 811             40-59               13 (13-14)                0.070                              0.10                   4-5 rounds, every 18 months

\*Annual and biennial groups share a common control group (n=15 394) which was split for the meta-analysis.

†Studies did not publish cancer specific mortality data to 12 years' follow-up.

‡Absolute risk reductions apply to patients aged 55-74 years only.

§Absolute risk reductions apply to all women, including those aged 40-54 years. Because we did not have access to the underlying data, we were unable to calculate confidence intervals for the published absolute risk reductions at eight and 12 years.

For breast cancer screening (using mammography), we examined population based, randomized controlled trials conducted in Sweden[@ref22] (Goteborg,[@ref23] Malmo I,[@ref24] Ostergotland,[@ref16] Stockholm[@ref25]) and the US (New York) (table 1).[@ref26] All five trials were large, ranging in size from 13 811 to 61 004 participants, and enrolling women aged 40-74 years. Participants in each study were randomized to receive an invitation to screen versus usual care. Screening regimens varied by individual trial (range 2-8 rounds of mammography). The primary outcome in these trials was breast cancer mortality, and follow-up ranged from 10 to 20 years.

Results from the four Swedish trials were combined into one study, stratified by age.[@ref22] Because of our focus on older patients, we relied on age stratified data (55-64 years; 65-74 years) provided by this paper. Thus, although the original data came from five trials, we pooled three mortality curves (Health Insurance Plan-New York, combined Swedish studies ages 55-64 years and 65-74 years).[@ref22] Although using the age stratified curves from the combined Swedish study prevented us from accounting for heterogeneity between individual Swedish trials, we were able to exclude most younger women (age 40-54 years) and focus on older women (55-74 years) for our analysis.

Data extraction
---------------

To combine data from individual studies into a summary best estimate of a pooled time lag to benefit, our goal was to obtain the annual number of cancer deaths and the annual number of participants at risk for each study.[@ref27] [@ref28] [@ref29] Only the Health Insurance Plan-New York study[@ref26] provided this information directly in table format; for all other studies, we determined annual cancer deaths and numbers at risk through the following protocol.

We emailed trial authors to request data for annual cancer mortality and annual numbers at risk. Two colorectal cancer trials (Nottingham and Goteborg) and one breast cancer trial (Two-County: Ostergotland) provided these data. If we were unable to obtain this data from trial authors, we examined the published mortality curves to determine the cause specific rate of mortality (usually per 1000 participants) each year. We followed the Messori procedure,[@ref28] scanning the survival curves and analyzing the scanned images to determine quantitative estimates of the annual rate of cause specific mortality. A subset of survival curves were scanned and analyzed independently (SO'B and JC-P) to ensure that our methodology was highly reproducible. We determined the annual number of cancer deaths by multiplying the annual risk of cause specific mortality by the annual number at risk.

The annual number at risk was determined using the initial sample size and the total person years of observation in the screening and control cohorts. To account for censoring owing to death for other reasons, we used country specific information from life tables[@ref30] [@ref31] and the average cohort age to estimate the number of participants each year who would die from all causes. We found that published data for the total person years of observation was lower than our calculated total, suggesting additional losses to follow-up. Thus, we calculated an additional constant annual proportion of participants who would be lost to follow-up and censored for each study (range 0.1-1.3%). For all studies, the control and intervention cohorts were treated identically, with the same rates of overall all cause mortality and the same proportion of additional losses to follow-up. Previous modeling studies suggest that survival meta-analyses with unavailable data for numbers at risk are robust to varying assumptions for numbers at risk.[@ref27]

Using the annual rates of death from breast or colorectal cancer in the intervention and control groups for each study, we reported the pooled absolute risk reductions by year, as well as the number of years needed to achieve specific thresholds of absolute risk reduction.

Statistical analysis
--------------------

To estimate a pooled time lag to benefit across trials, we extracted survival curves for the control and intervention groups for each study before combining the survival curves in our meta-analysis to obtain pooled estimates of absolute risk reduction.[@ref32] [@ref33] Specifically, we first used the annual rate of cause specific mortality and the annual number at risk for the control and intervention groups to determine control and intervention survival curves for each study. Then, as proposed by Ouwens and colleagues,[@ref34] we fit Weibull survival curves for each study's arm (control or intervention) using a joint random effects model on both the shape and scale parameters.

By modeling hazard over time while allowing for study specific variation in both hazard function parameters, we could retain randomized comparisons between the control and intervention groups. With survival curves for both the control and screened groups for each study, we calculated when specific absolute risk reduction thresholds were crossed in each study. We compared our Weibull survival functions with a Kaplan-Meier survival function, and found good fit in control and screened groups across all studies. This result suggested that Weibull curves were an appropriate modeling strategy for our data. For each study, we truncated the Weibull curves at the maximum follow-up time so that estimates of longer times to benefit were based on fewer studies.

Statistical inference for the model was performed by Markov chain Monte Carlo (MCMC) methods using a WinBUGS program (version 1.4.3, MRC Biostatistics) adapted from a previously published code.[@ref34] Using 200 000 MCMC simulations, we obtained meta-analyzed point estimates, standard errors, and confidence intervals for annual rates of cause specific mortality in controls and screened patients. These data allowed us to calculate annual absolute risk reductions. To determine the time lag to benefit, we calculated the time at which specific thresholds of absolute risk reduction (1:10 000, 1:5000, 1:2000, 1:1000, 1:500) were crossed for each MCMC simulation (both in individual studies and overall for the meta-analysis).

Results
=======

Colorectal cancer screening
---------------------------

For colorectal cancer screening, we examined the meta-analyses conducted by the Cochrane Collaboration in 2008[@ref11] and the US Preventive Services Task Force report in 2008[@ref1] and identified four trials. All four trials met inclusion criteria and were included in our meta-analysis: Minnesota,[@ref20] [@ref21] Nottingham,[@ref18] Funen,[@ref17] and Goteborg (fig 1).[@ref19] The Minnesota study had two intervention arms (annual and biennial screening), each compared with the one control arm; we split the control group and entered the two intervention arms separately into our meta-analysis.[@ref35]

After pooling these trials, we calculated the average mortality benefit. At five years, 2.8 deaths from colorectal cancer were prevented for 10 000 people screened (95% confidence interval −1.2 to 6.8; fig 2[](#fig2){ref-type="fig"}). Mortality benefits varied from study to study (web appendix 1). The benefit in colorectal cancer mortality increased steadily with longer follow-up, reaching 23 colorectal cancer deaths prevented for 10 000 people screened (3.0 to 42) at 15 years. For time lags to benefit at specific thresholds of absolute risk reduction, 4.8 years (2.0 to 9.7) were needed before one colorectal cancer death was prevented for 5000 people screened, and 10.3 years (6.0 to 16.4) were needed before one colorectal cancer death was prevented for 1000 persons screened. (table 2[](#tbl2){ref-type="table"})

The absolute benefits of screening increased faster at longer follow-up times. We found that 10.3 years were required for the absolute risk reduction to move from 0 to 0.001 (that is, from no colorectal cancer deaths prevented to one death prevented in 1000 people screened). However, only 4.3 additional years were required for the absolute risk reduction to increase from 0.001 to 0.002 (that is, from one to two deaths prevented in 1000 people screened).

![**Fig 2** Pooled mortality curves for colorectal cancer. Values are the number of deaths from colorectal cancer prevented per 1000 people screened (that is, the absolute risk reduction). \*P\<0.05](lees002063.f2_default){#fig2}
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Time lag to benefit (years) at specific thresholds of absolute risk reduction, for colorectal and breast cancer screening

                                                              Absolute risk reduction (95% CI)\*                                                                  
  ----------------------------------------------------------- ------------------------------------ -------------------- -------------------- -------------------- ---------------------
  **Colorectal cancer screening (fecal occult blood test)**                                                                                                       
  Minnesota (annual)                                          2.8 (0.5 to 8.7)                     3.5 (1.0 to 9.1)     5.3 (2.2 to 10.5)    7.4 (4.0 to 12.6)    13.7 (9.5 to 19.0)
  Minnesota (biennial)                                        9.9 (3.4 to 24.0)                    10.4 (2.4 to 22.1)   11.6 (6.0 to 20.6)   13.3 (8.2 to 20.4)   15.6 (11.5 to 20.6)
  Nottingham                                                  2.2 (0.6 to 5.2)                     3.3 (1.2 to 7.4)     6.1 (2.7 to 11.7)    10.4 (5.2 to 18.7)   15.7 (11.0 to 21.7)
  Funen                                                       2.2 (0.4 to 6.7)                     2.9 (0.7 to 7.9)     4.9 (1.8 to 10.8)    7.3 (3.8 to 12.6)    9.5 (7.6 to 11.7)
  Goteborg                                                    8.2 (3.0 to 18.8)                    9.1 (4.1 to 17.7)    11.0 (6.4 to 17.8)   13.4 (8.9 to 19.2)   16.5 (12.7 to 21.0)
  Summary                                                     3.7 (1.2 to 8.7)                     4.8 (2.0 to 9.7)     7.3 (3.8 to 12.7)    10.3 (6.0 to 16.4)   14.6 (9.6 to 21.2)
  **Breast cancer screening (mammography)**                                                                                                                       
  Health Insurance Plan-New York                              2.9 (0.8 to 7.3)                     3.7 (1.4 to 8.2)     5.7 (2.9 to 10.0)    7.9 (5.1 to 11.6)    9.7 (8.6 to 11.0)
  Combined Swedish trials (age 55-64 years)                   1.0 (0.4 to 2.2)                     1.9 (0.8 to 3.8)     4.3 (2.0 to 8.2)     8.9 (4.2 to 16.6)    16.2 (11.5 to 22.2)
  Combined Swedish trials (age 65-74 years)                   5.3 (0.4 to 25.7)                    6.3 (0.9 to 24.2)    8.8 (2.4 to 23.7)    12.0 (5.1 to 24.4)   15.8 (10.5 to 22.8)
  Summary                                                     1.8 (0.6 to 4.1)                     3.0 (1.1 to 6.3)     6.2 (2.3 to 13.3)    10.7 (4.4 to 21.6)   15.9 (9.4 to 25.2)

\*One death from colorectal or breast cancer prevented per 10 000 people screened (0.0001), per 5000 people screened (0.0002), per 2000 people screened (0.0005), per 1000 people screened (0.001), and per 500 people screened (0.002).

Breast cancer screening
-----------------------

For breast cancer screening, we started with the USPSTF meta-analyses conducted in 2002,[@ref10] the Cochrane Collaboration review in 2009,[@ref9] and the USPSTF review in 2009.[@ref2] We identified 10 trials. We excluded two mammography trials on the basis of the Cochrane quality ratings of "biased" (Edinburgh)[@ref15] or "likely biased" (Two County: Kopparberg).[@ref16] Three additional trials were excluded because they did not include women older than 50 years (Canadian National Breast Screening Study I,[@ref12] Malmo II,[@ref13] and UK Age[@ref14]), resulting in a total of five mammography trials (fig 1).

We used the combined Swedish study,[@ref22] which aggregated four Swedish trials,[@ref16] [@ref23] [@ref24] [@ref25] and presented the data stratified by age to focus on older participants aged 55-74 years. Thus, five trials were included in our meta-analysis: Stockholm,[@ref22] [@ref25] Goteborg,[@ref22] [@ref23] Two-County: Ostergotland,[@ref16] [@ref22] Malmo,[@ref22] [@ref24] and Health Insurance Plan-New York (table 1).[@ref26]

After pooling these trials, we calculated the average mortality benefit. At five years, 5.1 deaths from breast cancer were prevented for 10 000 women screened (95% confidence interval 1.2 to 9.0; fig 3[](#fig3){ref-type="fig"}). Web appendix 2 shows mortality curves for the individual studies. By 15 years, the benefit of mammography in cause specific mortality had increased to 19 deaths prevented for 10 000 women screened (−2 to 39). When we calculated the time lag to benefit to specific thresholds of absolute risk reduction, we found that 3.0 years (1.1 to 6.3) were required before one death from breast cancer was prevented for 5000 women screened (table 2), and 10.7 years (4.4 to 21.6) were required before one death was prevented for 1000 women screened.

![**Fig 3** Pooled mortality curves for breast cancer. Values are the number of deaths from breast cancer prevented per 1000 people screened (that is, the absolute risk reduction). \*P\<0.05](lees002063.f3_default){#fig3}

Discussion
==========

In this survival meta-analysis, we used novel methods to determine quantitative pooled estimates of the time lags to benefit for breast and colorectal cancer screening, based on data from high quality, randomized clinical trials. For colorectal cancer screening (by fecal occult blood testing), 4.8 years elapsed before one death from colorectal cancer was prevented for 5000 people screened, and 10.3 years elapsed before one death was prevented for 1000 people screened. For breast cancer screening (by mammography), 3.0 years elapsed before one death from breast cancer was prevented for 5000 women screened, and 10.7 years elapsed before one death was prevented for 1000 women screened.

Implications for targeting breast and colorectal cancer screening
-----------------------------------------------------------------

Different clinicians and patients might have differing perspectives on the probability of future mortality benefit that justifies the immediate risks and burdens of screening. Therefore, we presented a spectrum of time lags to benefit, corresponding to varying specific thresholds of absolute risk reduction. Some may view an absolute risk reduction of one death prevented in 10 000 people screened as a meaningful benefit. However, this small chance of benefit must be weighed against the chance of patients being harmed from screening.

For colorectal cancer screening, systematic reviews suggest that about one in 10 patients who are screened with fecal occult blood testing will have a false positive result,[@ref36] leading to worry and colonoscopy. Serious complications (such as perforation, major bleeding, and death) occur in 3.1 colonoscopies per 1000 screened.[@ref4] For mammography screening, systematic reviews also suggest that about one in 10 women screened will have a false positive result.[@ref37] They also suggest that one in 100 women screened will need a biopsy, and one in 1000 will be subject to overdiagnosis (that is, diagnosed with a breast cancer that was unlikely to have been clinically evident during their lifetime) and possibly unnecessary treatment.[@ref37]

The serious harms of screening occur at a rate of three in 10 000 to one in 1000 for colorectal cancer and breast cancer screening, respectively.[@ref4] [@ref37] As a result, an absolute risk reduction of one in 1000 is probably a reasonable threshold where the potential benefit likely outweighs the potential risks for most patients. Therefore, patients with a life expectancy greater than 10 years should be encouraged to undergo screening for colorectal cancer and breast cancer. Conversely, patients whose life expectancy is less than three to five years (that is, less than the time lag to an absolute risk reduction of one in 5000) probably should be discouraged from screening, since the potential risks probably outweigh the small probability of benefit.

Between these extremes is an intermediate zone of small or unclear benefit,[@ref38] in which patient preferences and values should have the dominant role in deciding whether screening is appropriate.[@ref39] Therefore, our results should not be used to deny screening for patients with limited life expectancy. Rather, our results should inform individualized decision making, which aims to account for patient preferences and values while maximizing benefits and minimizing risks.

Strengths and limitations of study
----------------------------------

One strength of this research is that we presented a spectrum of time lags to benefit corresponding to a range of thresholds of absolute risk reduction to help a wide range of patients make informed decisions on breast and colorectal cancer screening. Reasonable clinicians and patients might differ on the level of absolute risk reduction that justifies the small but immediate risks and burdens of screening. Further, certain comorbidities such as dementia could increase the risks of screening; for these patients, the higher immediate risks suggest that the absolute risk reduction must also be higher for cancer screening to be beneficial. Population recommendations often suggest a "one size fits all" approach for all patients of a certain age. However, the spectrum of absolute risk reductions and time lags to benefit in this study, used with individualized predictions of mortality risk, can promote tailored decision making across a wide range of patient preferences and life expectancies.

Our findings were subject to limitations. Firstly, since all trials examined multiple rounds of screening, we focused on the time lag to benefit for multiple rounds of screening. However, the patient and provider must make the decision to undergo (or forego) a screening test. Since the mortality benefit from one episode of screening must be less than from multiple episodes of screening, our results could have underestimated the true time lag to benefit for one screening test. Secondly, although avoiding death from cancer is a critical benefit, avoiding symptoms related to cancer is also important. Since cancer symptoms will usually precede cancer death, the time lag to avoiding cancer symptoms will be shorter than the time lag to avoiding cancer death. As a result, our results could have overestimated the time lag to benefit for avoiding cancer symptoms.

Thirdly, our study focused on cause specific mortality that could have been subject to ascertainment bias, owing to late or unexpected complications of screening or treatment not considered in rates of cause specific mortality. Although all cause mortality would have been less subject to bias, common cancers such as breast and colorectal cancer cause only less than 4% of deaths overall in the US.[@ref40] As a result, previous meta-analyses of breast and colorectal cancer screening showed no differences in all cause mortality between screened and unscreened groups.[@ref4] [@ref9] Thus, we focused on cause specific mortality, relying on previous reviews to identify high quality trials to minimize the risk of bias.

Fourthly, we relied on older studies of cancer screening that could have limited our ability to address current strategies of cancer screening. For breast cancer screening, modern mammography machines could be more accurate, and radiologists might now receive better training. For colorectal cancer screening, new high sensitivity guaiac tests probably have a higher detection rate than fecal occult blood tests. However, this new test could also lead to more false positive results, making its ultimate effect on colorectal cancer mortality unclear. Furthermore, three studies of screening flexible sigmoidoscopy have been published since 2009, which we were unable to incorporate owing to a lack of published survival curves[@ref41] and Cochrane or USPSTForce reviews on study quality.[@ref41] [@ref42] [@ref43] Finally, we plan to apply our methodology to the results of ongoing studies of screening colonoscopy, to determine whether the time lag to benefit for colonoscopy differs substantially from the time lag to benefit for fecal occult blood testing.

Finally, our meta-analysis could have obscured real differences in the time lag to benefit from different testing methods (for example, rehydrated *v* unrehydrated fecal occult blood testing), testing frequencies (for example, annual *v* biennial), and populations. For example, real differences in benefit across ages could have been missed, owing to differences in the rate of disease progression or incidence of cancer. However, studies of breast and colorectal cancer screening have shown no or conflicting evidence of differences in screening benefit across ages.[@ref4] [@ref22] In addition, many of our results have wide confidence intervals, precluding definitive comparisons across different populations. Future research should aim to obtain patient level data to reduce uncertainty and obtain more precise estimates of the time lags to benefit.

Conclusions and implications for practice guidelines
----------------------------------------------------

In this study, we have determined pooled estimates of the time lags to benefit for breast and colorectal cancer screening across a spectrum of absolute risk reduction thresholds. Based on study populations predominantly aged over 50 years, it takes 4.8 years on average for fecal occult blood test screening to prevent one death from colorectal cancer in 5000 people screened, suggesting that for most patients with a life expectancy of shorter than five years, the harms of screening likely outweigh the benefits. It takes 10.3 years to prevent one death from colorectal cancer for 1000 patients screened, suggesting that for most patients with a life expectancy greater than ten years the benefits likely outweigh the harms.

For breast cancer screening by mammography, it takes only 3.0 years to prevent one death per 5000 women screened, suggesting that for most women with a life expectancy less than three years, the harms likely outweigh the benefits. It takes 10.7 years to prevent one death from breast cancer for 1000 women screened, suggesting that for most women with a life expectancy greater than 10 years the benefits outweigh the harms. Incorporating time lag estimates into screening guidelines would encourage a more explicit consideration of the risks and benefits of screening for breast and colorectal cancer. This would probably result in a more individualized process of decision making for the heterogeneous population of older adults.

### What is already known on this topic

1.  Guidelines recommend targeting cancer screening to healthier older patients; the complications from screening can harm patients immediately, while the benefits are not seen for many years

2.  The time lag to a survival benefit for breast and colorectal cancer screening is uncertain

### What this study adds

1.  Screening for colorectal cancer (fecal occult blood testing) or breast cancer (mammography) takes roughly 10 years on average to prevent one death for every 1000 patients screened

2.  Screening for breast and colorectal cancer should be targeted toward those patients with a life expectancy greater than 10 years
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